Quantcast

Latest Inflammatory bowel disease Stories

2014-02-26 08:28:31

OKLAHOMA CITY, Feb. 26, 2014 /PRNewswire/ -- Altheus Therapeutics, Inc., announced completion of dosing in ZA201, a double-blind, active-controlled Phase 2 trial evaluating the efficacy and safety of Zoenasa® Rectal Gel versus mesalamine enema in 120 patients with left-sided ulcerative colitis. The primary endpoint of ZA201 is reduction in the Ulcerative Colitis Disease Activity Index (UCDAI) at 6 weeks. Secondary endpoints include endoscopic remission, reduction in UCDAI at 3...

2014-02-04 04:21:48

LONDON, February 4, 2014 /PRNewswire/ -- Shield Therapeutics (Shield), an independent specialty pharmaceutical company, today announces the acceptance of the first peer-reviewed abstract relating to data from the AEGIS Phase III programme of ST10 for the treatment of iron deficiency anaemia (IDA) in inflammatory bowel disease (IBD). The data will be presented at the 9th Congress of ECCO, taking place from February 20 - 22 in Copenhagen, Denmark. As recently announced,...

2014-01-29 12:27:38

OKLAHOMA CITY, Jan. 29, 2014 /PRNewswire/ -- Altheus Therapeutics, Inc. announced the USPTO has allowed patent 8,629,127 B2 covering the oral pharmaceutical composition 5-ASA (5-aminosalicylic acid) and NAC (N-acetylcysteine). Combination therapy patents are uncommon and under-appreciated in the pharmaceutical industry because the Patent Office requires surprising, unexpected, or synergistic benefits from combining active ingredients into a single formulation. Altheus' success in...

2014-01-16 16:24:09

AUSTIN, Texas, Jan. 16, 2014 /PRNewswire/ -- XBiotech announced today that it has launched a Phase II study to treat a rare but debilitating disorder, Pyoderma Gangrenosum (PG). This study is based on efficacy seen with anti-IL-1 therapeutic antibody in previous dermatological clinical studies such as psoriasis and acne. PG is expected to be considered an "orphan indication" by the FDA, facilitating expedited clinical development to market. Dr. Armand Cognetta, lead clinical...

2014-01-15 08:29:25

Collaboration Brings Unique Expertise Together THOUSAND OAKS, Calif., Jan. 15, 2014 /PRNewswire/ -- Massachusetts General Hospital (MGH), the Broad Institute, and Amgen (NASDAQ:AMGN) announced today that they have launched a strategic collaboration to jointly discover and validate new therapeutic targets and develop novel therapies for inflammatory bowel disease (IBD), a chronic disorder that affects millions worldwide. The MGH-Broad-Amgen collaboration brings together...

2014-01-09 08:28:44

OKLAHOMA CITY, Jan. 9, 2014 /PRNewswire/ -- Altheus Therapeutics, Inc., announced that it has completed enrollment for ZA201, a 6-week, double-blind, active-controlled Phase 2 clinical trial of the efficacy and safety of Zoenasa® Rectal Gel in approximately 120 adult patients with left-sided, or distal, ulcerative colitis. Topline results are expected in to be available in March or early April. (Logo: http://photos.prnewswire.com/prnh/20140109/DA43446LOGO) "Positive ZA201...

2014-01-07 04:21:03

LONDON, January 7, 2014 /PRNewswire/ -- ~ ST10 strongly demonstrates potential to be (1) the only effective oral treatment for ferrous intolerant IDA patients and (2) an effective alternative to intravenous iron treatment ~ Shield Therapeutics (Shield), an independent specialty pharmaceutical company focused on the development of mineral-derived hospital pharmaceuticals, today announces strongly positive top-line data from...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related